Genmab announces new data from Phase 1/2 RAINFOL-01 trial

Genmab (GMAB) announced updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan, an investigational folate receptor alpha-targeted, TOPO1-inhibitor antibody-drug conjugate, ADC. The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m every 3 weeks, Q3W, resulted in a 50.0% confirmed objective response rate, ORR, including two complete responses, CR, in heavily pretreated patients with advanced endometrial cancer, EC, who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders in the 100 mg/m cohort maintained their responses and remain on treatment. The responses were observed regardless of FRalpha expression levels. The updated results were presented at the European Society for Medical Oncology, ESMO, Congress in Berlin, Germany.